With strong three-month performance and significant upside potential, Shattuck Labs, Inc. (NASDAQ:STTK) secures a spot on our list of the 12 hot penny stocks to invest in right now.
Pixabay/Public Domain
Highlighting the SL-325’s Phase 1 readout, expected in Q2 2026, H.C. Wainwright’s Joseph Pantginis reiterated a “Hold” rating on Shattuck Labs, Inc. (NASDAQ:STTK) on November 7, 2025. The analyst believes the drug holds significant clinical potential, boosting the analyst’s confidence. The drug remains a key growth catalyst, with DR3-based bispecific antibodies expected to provide longer-term upside. Pantginis also cited the company’s solid financial position as visible through its cash and investments balance of $86.10 million. Thus, the analyst sees a balanced risk profile for the company, with SL-325 remaining central to the investment case.
Meanwhile, Shattuck Labs, Inc. (NASDAQ:STTK) announced its third-quarter 2025 results on November 6, 2025. The company, still in its development stage, noted R&D declining to $7.60 million, while G&A expenses totaled $4.10 million. Reflecting disciplined execution, Shattuck Labs reaffirmed advancement of the Phase 1 SL-325 trial. It also reported continued progress toward selecting a bispecific candidate in 2026. With a healthy cash balance, the company looks well-positioned to advance the drug into Phase 2 trials. Net loss for the quarter was $10.1 million, or $0.14 per basic and diluted share.
Shattuck Labs, Inc. (NASDAQ:STTK) focuses on developing novel therapies for autoimmune and inflammatory diseases. Its SL-325 drug aims for a complete blockade of the validated DR3/TL1A pathway.s
While we acknowledge the potential of STTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.
Disclosure: None.
